Aclaris Therapeutics, Inc. (ACRS)

1.2600 +0.0500 (+4.13%) 收市：04:00PM EDT

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 86

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Neal S. Walker D.O., M.D.	Co-Founder, President, Chairman & Interim CEO	73.5k	無	1970
Mr. Kevin Balthaser	Chief Financial Officer	581.52k	無	1988
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer	492.43k	無	1957
Mr. James Loerop	Chief Business Officer	570k	無	1965
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary	無	無	無
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry	無	無	無
Mr. Steve Tucker	Senior Vice President of Project Leadership	無	無	無
Mr. Ajay Aggarwal M.B.A., M.D.	Senior Vice President of Clinical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

公司管治

截至 2024年4月29日 止，Aclaris Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：8；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。